PFE

2023 Humankind 100 List Announced Today

Retrieved on: 
Monday, July 24, 2023

Humankind Investments , a quantitatively driven asset manager specializing in socially responsible investments, announced today the release of 2023’s “Humankind 100,” its annual ranking of the top U.S. companies offering the greatest benefit to humanity, based on Humankind Investments’ proprietary Humankind Value methodology.

Key Points: 
  • Humankind Investments , a quantitatively driven asset manager specializing in socially responsible investments, announced today the release of 2023’s “Humankind 100,” its annual ranking of the top U.S. companies offering the greatest benefit to humanity, based on Humankind Investments’ proprietary Humankind Value methodology.
  • “We launched the Humankind 100 with a two-fold purpose – to help people understand the companies best supporting their quality of life and to encourage companies to continue striving for progress,” said James Katz, founder and CEO of Humankind Investments.
  • The ranking was calculated using Humankind Investments’ proprietary Humankind Value methodology, which tends to favor companies that promote human health and improved quality of life.
  • “By publishing these rankings each year we’re optimistic that we can motivate companies to make progress on their own human impact.”

Pfizer Announces Post-Tornado Relief Plans for Rocky Mount Community and Manufacturing Facility

Retrieved on: 
Friday, July 21, 2023

All 3,200 local Pfizer colleagues reporting to this manufacturing site are safe and accounted for after excellent implementation of the site’s long-standing evacuation plan.

Key Points: 
  • All 3,200 local Pfizer colleagues reporting to this manufacturing site are safe and accounted for after excellent implementation of the site’s long-standing evacuation plan.
  • Pfizer also announced a donation to the American Red Cross North Carolina Chapter and United Way Tar River Region to support the relief and recovery needs.
  • Pfizer is also exploring alternative manufacturing locations for production across our significant manufacturing presence in the U.S. and internationally and across the company’s partner network.
  • The site is one of 10 Pfizer manufacturing sites located in the United States.

Pfizer Announces New England Journal of Medicine Publication on Group B Streptococcus (GBS) Maternal Vaccine Candidate

Retrieved on: 
Wednesday, July 19, 2023

Pfizer Inc. (NYSE: PFE) today announced data from a Phase 2 study investigating its hexavalent capsular polysaccharide (CPS) conjugate Group B Streptococcus (GBS) vaccine candidate, GBS6, being developed for maternal administration to protect infants against invasive GBS disease.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced data from a Phase 2 study investigating its hexavalent capsular polysaccharide (CPS) conjugate Group B Streptococcus (GBS) vaccine candidate, GBS6, being developed for maternal administration to protect infants against invasive GBS disease.
  • The results were published in The New England Journal of Medicine (NEJM) and will inform a planned Phase 3 clinical development program.
  • In both the mothers and infants, the safety profile was similar between the vaccine and placebo groups.
  • Solicited systemic events were similar among the GBS6 groups and the placebo group, with most events being mild or moderate.

Flagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs

Retrieved on: 
Tuesday, July 18, 2023

CAMBRIDGE, Mass. and NEW YORK, July 18, 2023 /PRNewswire/ -- Flagship Pioneering, Inc. and Pfizer Inc. (NYSE: PFE) today announced the companies have partnered to create a new pipeline of innovative medicines. Under the terms of the novel agreement, Flagship and Pfizer will each invest $50M upfront to explore opportunities to develop 10 single-asset programs by leveraging Flagship's ecosystem of more than 40 human health companies and multiple biotechnology platforms. Pfizer will fund and have an option to acquire each selected development program. Flagship and its bioplatform companies will be eligible to receive up to $700M in milestones and royalties for each successfully commercialized program.

Key Points: 
  • and NEW YORK, July 18, 2023 /PRNewswire/ -- Flagship Pioneering, Inc. and Pfizer Inc. (NYSE: PFE) today announced the companies have partnered to create a new pipeline of innovative medicines.
  • Pioneering Medicines, an initiative of Flagship Pioneering, working in collaboration with Pfizer's research and development leadership, will lead the exploration process to drive rapid potential portfolio creation.
  • "Flagship and Pfizer enter into this strategic alliance driven by a shared sense of urgency to develop novel medicines that make a difference for patients," said Paul Biondi, President, Pioneering Medicines, and Executive Partner, Flagship Pioneering.
  • "This collaboration is an exciting opportunity for Pfizer to bring deep scientific expertise and apply our development and regulatory strength to Flagship's diverse portfolio of technology platforms, translating early-stage innovation to potential medicines."

Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination

Retrieved on: 
Thursday, July 6, 2023

DUBLIN, Ireland and BOSTON, July 06, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced a clinical trial collaboration and supply agreement with Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE).

Key Points: 
  • DUBLIN, Ireland and BOSTON, July 06, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced a clinical trial collaboration and supply agreement with Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE).
  • This agreement covers the execution of a Phase 1b/2 clinical trial to evaluate the novel combination of Carrick’s samuraciclib (CT7001), an oral and first-in-class inhibitor of CDK7, and Arvinas’ vepdegestrant (ARV-471), an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader being developed in collaboration with Pfizer, in patients who have received prior CDK4/6i, with ER+, HER2- metastatic breast cancer.
  • “We’re pleased to announce our collaboration with Arvinas and Pfizer to explore the potential of samuraciclib in combination with vepdegestrant for the treatment of advanced breast cancer,” said Tim Pearson, Chief Executive Officer of Carrick Therapeutics.
  • It is anticipated that the Phase 1b/2 trial will be initiated in the second half of 2023.

Caribou Biosciences Announces $25 Million Equity Investment from Pfizer

Retrieved on: 
Thursday, July 6, 2023

BERKELEY, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 million equity investment in the company. Pfizer purchased 4,690,431 of Caribou common shares at a price of $5.33 per share, pursuant to the terms of a Securities Purchase Agreement dated June 29, 2023. The purchase by Pfizer closed on June 30, 2023. In conjunction with the investment, Sriram Krishnaswami, PhD, has joined Caribou’s Scientific Advisory Board.

Key Points: 
  • -- Sriram Krishnaswami, PhD, vice president and development head, multiple myeloma, Pfizer Global Product Development, has joined Caribou’s Scientific Advisory Board --
    BERKELEY, Calif., July 06, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Pfizer Inc. (NYSE: PFE) has made a $25 million equity investment in the company.
  • Pfizer purchased 4,690,431 of Caribou common shares at a price of $5.33 per share, pursuant to the terms of a Securities Purchase Agreement dated June 29, 2023.
  • The purchase by Pfizer closed on June 30, 2023.
  • Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.

FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency

Retrieved on: 
Wednesday, June 28, 2023

Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone.
  • The study met its primary endpoint of NGENLA non-inferiority compared to somatropin, as measured by annual height velocity at 12 months.
  • “The approval of NGENLA will be significant for children with growth hormone deficiency in the U.S.
  • It holds potential to reduce the treatment burden that can come with daily growth hormone injections,” said Joel Steelman, M.D., Pediatric Endocrinologist, Cook Children’s Health Care System.

FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec

Retrieved on: 
Tuesday, June 27, 2023

Fidanacogene elaparvovec is a novel, investigational gene therapy that contains a bio-engineered adeno-associated virus (AAV) capsid (protein shell) and a high-activity variant of human coagulation Factor IX (FIX) gene.

Key Points: 
  • Fidanacogene elaparvovec is a novel, investigational gene therapy that contains a bio-engineered adeno-associated virus (AAV) capsid (protein shell) and a high-activity variant of human coagulation Factor IX (FIX) gene.
  • “Gene therapy marks a new era of scientific advancement, and if approved, we believe fidanacogene elaparvovec has the potential to transform the lives of people living with hemophilia B who are eligible for treatment.
  • Fidanacogene elaparvovec has been granted Breakthrough, Regenerative Medicines Advanced Therapy (RMAT) and orphan drug designations from the FDA.
  • Pfizer currently has three Phase 3 programs investigating gene therapy in populations where there is a high unmet need: hemophilia B, hemophilia A, and Duchenne muscular dystrophy.

Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus

Retrieved on: 
Monday, June 26, 2023

Pfizer Inc. (NYSE: PFE) today announced its decision to continue to progress one oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate toward further clinical development for the potential treatment of adults with obesity and Type 2 diabetes mellitus (T2DM).

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced its decision to continue to progress one oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate toward further clinical development for the potential treatment of adults with obesity and Type 2 diabetes mellitus (T2DM).
  • Moving forward, the company will continue advancing the clinical program for danuglipron (PF-06882961), subject to results from the ongoing Phase 2 trial, and discontinue the clinical development of lotiglipron (PF-07081532).
  • The company expects to finalize plans for the danuglipron late-stage program by the end of 2023 and also is developing a once-daily modified release version.
  • Data from these studies evaluating lotiglipron will be presented at a scientific conference or published in peer-reviewed journal(s).

FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata

Retrieved on: 
Friday, June 23, 2023

It is the first and only treatment approved by the FDA for adolescents (12+) with severe alopecia areata.

Key Points: 
  • It is the first and only treatment approved by the FDA for adolescents (12+) with severe alopecia areata.
  • “LITFULO is an important treatment advancement for alopecia areata, an autoimmune disease that previously had no FDA-approved options for adolescents and limited options available for adults,” said Angela Hwang, Chief Commercial Officer, President, Global Biopharmaceuticals Business, Pfizer.
  • “With today’s approval, adolescents and adults who struggle with substantial hair loss have an opportunity to achieve significant scalp hair regrowth.”
    The FDA approval was based on results of clinical trials in alopecia areata.
  • “We believe the approval of LITFULO is a significant advancement for the treatment of alopecia areata, particularly for teens.